Vir Biotechnology paid its 4 named executives $13.8M in total in FY2025 (Dec). CEO Marianne De Backer, M.Sc., Ph.D., MBA was paid $7.8M of that.
Pay$100 in the stock at the end of FY22 → $24
Pay of each named executive
Marianne De Backer, M.Sc., Ph.D., MBAPresident, Chief Executive Officer and Director
| FY2025 (Dec) | |||||||
| FY2024 (Dec) | |||||||
| FY2023 (Dec) |
3 years
Mark Eisner, M.D., M.P.H.Executive Vice President and Chief Medical Officer
| FY2025 (Dec) | |||||||
| FY2024 (Dec) |
2 years
Jason O’Byrne, MBAExecutive Vice President and Chief Financial Officer
| FY2025 (Dec) | |||||||
| FY2024 (Dec) |
2 years
Vanina de Verneuil, J.D.Executive Vice President, General Counsel and Corporate Secretary
| FY2025 (Dec) | |||||||
| FY2024 (Dec) |
2 years
CEO pay against the pay peers
In FY2025 (Dec), the median CEO pay of the 6 peers with pay on file was $5.4M. The CEO of Vir Biotechnology was paid $7.8M, 44% above the median.
- 1Ultragenyx Pharmaceutical
- 2Novavax
- 3Vir BiotechnologyThis company
- 4Beam Therapeutics
- 5Intellia Therapeutics
- 6Denali Therapeutics
- 7Relay Therapeutics
- 8Allogene Therapeutics, Inc.Not disclosed
- 9Arrowhead PharmaceuticalsNot disclosed
- 10Dynavax TechnologiesNot disclosed
- 11Editas Medicine Inc.Not disclosed
- 12IGM BiosciencesNot disclosed
- 13Iovance BiotherapeuticsNot disclosed
- 14Janux TherapeuticsNot disclosed
- 15REGENXBIO Inc.Not disclosed
- 16Replimmune GroupNot disclosed
- 17XencorNot disclosed
- 18iTeos TherapeuticsNot disclosed
Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.